Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Major depressive episodes (MDEs) occur frequently during the course of psychotic disorders,
and several antidepressive agents have been successfully applied. The new melatonergic
antidepressant agomelatine (AGO) appears promising for the treatment of MDEs in schizophrenia
for several reasons. The investigators plan to test the efficacy and tolerability of AGO for
antidepressive treatment in schizophrenia. For this task, the investigators plan to enrol 27
schizophrenic patients into an open, single-armed, prospective clinical trial with
agomelatine.